Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015

Description:

Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015

Summary

The authors, 'Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2015', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

The authors report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The authors proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by The authors team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction

REPORT COVERAGE
Adenocarcinoma of the Gastroesophageal Junction Overview
Therapeutics Development
Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction - Overview
Adenocarcinoma of the Gastroesophageal Junction - Therapeutics under Development by Companies
Adenocarcinoma of the Gastroesophageal Junction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adenocarcinoma of the Gastroesophageal Junction - Products under Development by Companies
Adenocarcinoma of the Gastroesophageal Junction - Companies Involved in Therapeutics Development
AB Science SA
Amgen Inc.
ArQule, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Adenocarcinoma of the Gastroesophageal Junction - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
(tipiracil hydrochloride + trifluridine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress

alpelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-5745 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Her-VAXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMAB-362 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indusatumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipilimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBP-426 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solitomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tivantinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action

R&D Progress

trastuzumab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

trastuzumab emtansine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Adenocarcinoma of the Gastroesophageal Junction - Recent Pipeline Updates

Adenocarcinoma of the Gastroesophageal Junction - Dormant Projects

Adenocarcinoma of the Gastroesophageal Junction - Discontinued Products

Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones

Featured News & Press Releases

Jul 01, 2015: Phase 1b/2 Gastric Cancer Trial on Track with Contract Research Organisation Appointed to Conduct Trial

Jun 01, 2015: Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitor BBI608 in Multiple Cancer Types

May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting

Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd...1)
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Johnson & Johnson, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by OncobioLogics, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd...1), H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3507621/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3507621/">http://www.researchandmarkets.com/reports/3507621/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD22DOQ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World